Valneva has met its revenue growth target for 2024, fending off slower-than-expected sales for the chikungunya vaccine Ixchiq. The French vaccine specialist posted total revenues of €169.6m ($ ...
H.C. Wainwright lowered the firm’s price target on Valneva (VALN) to $17 from $18 and keeps a Buy rating on the shares following the Q4 report. The firm cites reduced sales estimates for Ixchiq ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback